Hikma Pharmaceuticals Stock

Hikma Pharmaceuticals Market capitalization 2024

Hikma Pharmaceuticals Market capitalization

5.63 B USD

Ticker

HIK.L

ISIN

GB00B0LCW083

WKN

A0HG69

In 2024, Hikma Pharmaceuticals's market cap stood at 5.63 B USD, a -98.99% increase from the 555.22 B USD market cap in the previous year.

The Hikma Pharmaceuticals Market capitalization history

YEARMarket Capitalization (undefined USD)
2023488.59
2022469.52
2021767.75
2020701.87
2019563.99
2018469.44
2017472.17
2016660.83
2015675.06
2014544.41
2013314.7
2012220.49
2011226.9
2010207.8
2009131.32
2008154.85
2007143.91
2006126.7
200584.97
2004-

Hikma Pharmaceuticals Aktienanalyse

What does Hikma Pharmaceuticals do?

Hikma Pharmaceuticals PLC is a global company that focuses on the manufacturing and distribution of high-quality generics and specialty medications. The company was founded in Jordan in 1978 and is headquartered in London, UK. Over the years, Hikma Pharmaceuticals PLC has consistently grown and is now one of the leading generic manufacturers worldwide. The company operates in three core business areas: generics, injectables, and branded pharmaceuticals. It specializes in producing medications for diseases such as HIV/AIDS, cancer, and cardiovascular diseases. It also manufactures generics for anesthesia and opioid painkillers. In addition, Hikma Pharmaceuticals PLC produces injectable medications, particularly sterile injectables, used in emergency medicine, intensive care, and oncology. The company also develops proprietary medications based on specific patient needs and has its own pipeline of branded pharmaceuticals. It distributes over 1,000 medications in more than 50 countries, with production facilities in several countries including Jordan, Saudi Arabia, Portugal, Italy, and the United States. Hikma Pharmaceuticals PLC has shown strong performance in recent years, reflected in positive financial results. It prioritizes efficient production, strict quality standards, and smart investments to strengthen its market presence and innovation capability. The company has built a reputation as a reliable partner for customers and investors. In summary, Hikma Pharmaceuticals PLC is a global company engaged in the production and distribution of generics, injectables, and proprietary medications. It is known for its high-quality and cost-effective generics, broad product range, and strong international network. The company has established itself as a trusted partner for customers and investors and will continue to play a significant role in the pharmaceutical industry. Hikma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Hikma Pharmaceuticals's Market Capitalization

Hikma Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Hikma Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Hikma Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Hikma Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Hikma Pharmaceuticals stock

What is the current Hikma Pharmaceuticals market capitalization?

The current market capitalization of Hikma Pharmaceuticals is 5.63 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Hikma Pharmaceuticals.

How has the market capitalization of Hikma Pharmaceuticals developed in recent years?

The market capitalization of Hikma Pharmaceuticals has increased/decreased by -98.99% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Hikma Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Hikma Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Hikma Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Hikma Pharmaceuticals pay?

Over the past 12 months, Hikma Pharmaceuticals paid a dividend of 0.49 USD . This corresponds to a dividend yield of about 1.95 %. For the coming 12 months, Hikma Pharmaceuticals is expected to pay a dividend of 0.52 USD.

What is the dividend yield of Hikma Pharmaceuticals?

The current dividend yield of Hikma Pharmaceuticals is 1.95 %.

When does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of September, April, September, September.

How secure is the dividend of Hikma Pharmaceuticals?

Hikma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hikma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.52 USD are expected. This corresponds to a dividend yield of 2.05 %.

In which sector is Hikma Pharmaceuticals located?

Hikma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hikma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hikma Pharmaceuticals from 9/20/2024 amounting to 0.32 USD, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Hikma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Hikma Pharmaceuticals in the year 2023?

In the year 2023, Hikma Pharmaceuticals distributed 0.442 USD as dividends.

In which currency does Hikma Pharmaceuticals pay out the dividend?

The dividends of Hikma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hikma Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hikma Pharmaceuticals

Our stock analysis for Hikma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hikma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.